Humanigen Inc (HGENQ)

[DonDonDonDon]

Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS

https://ir.humanigen.com/English/news/news-details/2022/Humanigen-Announces-Peer-Reviewed-Publication-Demonstrating-the-Potential-Clinical-and-Economic-Benefits-of-Lenzilumab-from-the-Perspective-of-the-NHS/default.aspx

-In a weekly cohort of 4,754 newly hospitalized patients, addition of lenzilumab to standard of care (SOC) could result in over £5.5 million in cost savings weekly

-Lenzilumab plus SOC resulted in per-patient cost savings between £8,462 and £17,277 (net savings of £1,162 - £9,977) depending on patient population

-The number of COVID-19 cases continues to remain high with approximately 20,000 patients currently hospitalized in the UK,2 demonstrating the urgent need for both clinically effective and cost-effective variant-agnostic treatments for hospitalized patients

SHORT HILLS, N. J.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced a peer-reviewed publication in ClinicoEconomics and Outcomes Research outlining the potential clinical and health economic benefits of lenzilumab, if authorized or approved for use in the United Kingdom.

“As COVID-19 continues to place significant burden on the National Health Service (“NHS”), this paper demonstrates there is an opportunity to realize significant cost savings for healthcare systems of the UK while improving outcomes for patients. As a variant-agnostic treatment, lenzilumab may offer both a clinically effective and cost-effective option against current and emerging variants,” said Adrian Kilcoyne, M.D., Chief Medical Officer, Humanigen, the lead author of the publication.

The publication demonstrated, in all cases, lenzilumab plus SOC improved all specified clinical outcomes compared with SOC alone. Additionally, patient selection, utilizing CRP<150 mg/L as a biomarker, optimized both clinical and economic outcomes.The observed cost savings are mainly driven by fewer bed days, days on invasive mechanical ventilation and ICU days.

The greatest per-patient cost savings were for patients aged <85 years, CRP <150 mg/L, and receiving remdesivir of £10,427 (net savings of £3,127 after expected lenzilumab acquisition costs); and for Black patients with CRP <150 mg/L of £17,277 (net savings of £9,977).

“During these unprecedented and challenging times, we are preparing to commercialize lenzilumab, if authorized or approved, as a single day treatment and a potential driver of clinical and economic value to patients and the healthcare system,” said Edward Jordan, Chief Commercial Officer, Humanigen.

This peer-reviewed publication highlights the significant costs of treating hospitalized COVID-19 patients and the economic benefits of potentially improving survival without ventilation, reducing ventilator use, hospital days and ICU days which may be associated with adding lenzilumab to standard of care.

Lenzilumab is an investigational product and is not approved or authorized in any country.